FDA/CDC

FDA OKs new ‘artificial pancreas’ Medtronic 770G


 

The Food and Drug Administration has approved the MiniMed 770G (Medtronic) automated insulin delivery system for children aged 2-6 years.

The 770G system adds Bluetooth smartphone connectivity to the SmartGuard technology that is present in the hybrid closed-loop MiniMed 670G system, which has been available in the United States since 2016 for individuals aged 14 years and older who have type 1 diabetes. It has been available since 2018 for children aged 7 years.

The 770G will also be available to older children and adults once it has been launched.

As with other so-called artificial pancreas systems, the 770G is made up of an insulin pump and continuous glucose monitor that are connected via software that allows the pump to deliver or withhold insulin on the basis of glucose readings.

It is a “hybrid closed-loop” system in that users or caregivers must still manually signal carbohydrate consumption.

The 770G includes a “share” feature that allows health care providers, users, and caregivers to follow the user’s glucose levels remotely via smartphones. In-app notices indicate when glucose levels are out of range. The data can be uploaded prior to telehealth visits.

The approval was based on a 3-month study of 151 children aged 2-6 years who showed improvement in outcomes comparable with those seen in 124 older adolescents and adults with the 770G system as compared to patients who used manual (nonlooped) mode over a 2-week period. There were no episodes of severe hypoglycemia or diabetic ketoacidosis and no serious device-related adverse events while in hybrid closed-loop mode.

The FDA will require Medtronic to conduct a postmarketing study to evaluate the 770G in real-world settings. It is not approved for use in children younger than 2 years nor in any patient who requires less than 8 units of insulin per day.

The next-generation Medtronic closed-loop system, the 780G, has already been approved in Europe. It improves on the technology by delivering automated bolus correction doses in addition to basal insulin every 5 minutes. The company is preparing to submit the 780G for approval in the United States.

A version of this article originally appeared on Medscape.com.

Recommended Reading

Hyperglycemia predicts COVID-19 death even without diabetes
Journal of Clinical Outcomes Management
Good for profits, good for patients: A new form of medical visits
Journal of Clinical Outcomes Management
Novel program cuts weight retention after gestational diabetes
Journal of Clinical Outcomes Management
Cleaner data confirm severe COVID-19 link to diabetes, hypertension
Journal of Clinical Outcomes Management
Dapagliflozin Improves Cardiovascular Outcomes in Patients With Heart Failure and Reduced Ejection Fraction
Journal of Clinical Outcomes Management
COVID-19 taking financial toll on people in U.S. with diabetes
Journal of Clinical Outcomes Management
Guidance covers glycemia in dexamethasone-treated COVID-19 patients
Journal of Clinical Outcomes Management
Does metformin reduce risk for death in COVID-19?
Journal of Clinical Outcomes Management
DAPA-CKD: SGLT2 inhibitor benefit extends to chronic kidney disease without diabetes
Journal of Clinical Outcomes Management
Black diabetics lose limbs at triple the rate of others. Here’s how health care leaders are starting to act.
Journal of Clinical Outcomes Management